Invoices for C-II's, C-III's, C-IV's, and C-V's must be filed together. Is this statement true or false?

The statement is false; invoices for controlled substances, including C-II, C-III, C-IV, and C-V drugs, must be filed separately. In the context of the regulations governing the handling of controlled substances in pharmacies, each schedule has specific requirements and regulations regarding record-keeping and inventory management.

C-II drugs, due to their higher potential for abuse and associated stringent regulatory controls, have separate record-keeping requirements compared to C-III, C-IV, and C-V drugs. This separation helps facilitate accurate tracking and monitoring of these medications, ensuring compliance with federal and state laws. While C-III, C-IV, and C-V drugs may be grouped together for certain record-keeping purposes because they share lower restrictions, invoices related to C-II substances must always be maintained in a distinct file.

This distinction is crucial for maintaining compliance with regulatory requirements and ensuring the accurate auditing of pharmacy operations.